Recombinant Human PGF/PIGF protein (His Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

His Tag

Activity

not tested

Cat no : Eg0653

---

Validation Data Gallery

• 

  Purity of Recombinant Human PGF was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human PGF/PIGF protein Ala21-Arg149 (Accession# P49763-2) with a His tag at the C-terminus.
• GeneID: 5228
• Accession: P49763-2
• PredictedSize: 15.6 kDa
• SDS-PAGE: 18-25 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

PlGF (placenta growth factor), also named as PGF, is an angiogenic factor which belongs to vascular endothelial growth factor (VEGF) family. The human PlGF gene is located on chromosome 14q14 and encodes 4 isoforms of PlGF. The protein is secreted as a glycosylated homodimer and PlGF-1 and -3 are diffusible isoforms whereas PlGF-2 and PlGF-4 have heparin binding domains. PlGF was originally identified in the placenta, where it regulates growth and differentiation of trophoblasts. It is also expressed in umbilical vein endothelial cells and other non-placental tissues, like the thyroid gland and developing lung tissue. PlGF has angiogenic properties, enhancing survival, growth and migration of endothelial cells in vitro, and promotes vessel formation in certain in-vivo models. Serum levels of PIGF and sFlt-1 (also known as soluble VEGF receptor-1) are altered in women with preeclampsia. PIGF is a potential biomarker for preeclampsia, a condition in which blood vessels in the placenta are too narrow, resulting in high blood pressure.

References:

1.KhalilA.etal.(2008)PLoSOne.23;3(7):e2766.
2.DewerchinM.etal.(2012)ColdSpringHarbPerspectMed.1;2(8).
3.OuraH.et.at.(2003)Blood.101(2):560-7.
4.DuhigKE.etal.(2019)Lancet.393(10183):1807-1818.